9. Đặc điểm lâm sàng, cận lâm sàng và kết quả điều trị củng cố Durvalumab sau hóa xạ đồng thời ung thư phổi không tế bào nhỏ giai đoạn III

Abstract

The standard treatment for unresectable stage III non-small cell lung cancer (NSCLC) is concurrent chemoradiotherapy (CCRT) followed by durvalumab consolidation if there is no disease progression after CCRT. Currently, there are very few studies on Vietnamese NSCLC patients treated with durvalumab. This study aimed to evaluate the clinical and subclinical characteristics as well as the outcomes of durvalumab consolidation therapy in a Vietnamese patient population. This is a descriptive longitudinal study of 49 stage III NSCLC patients who received durvalumab consolidation therapy at K Hospital from March 2021 to March 2025, aiming to assess the effectiveness and tolerability of the regimen. The study found that the mean age was 60.9 ± 9.7 years, with the majority of patients under 65 years old (61.2%). Male patients accounted for 81.6%, and 71.4% had a history of smoking. About 75.5% had an ECOG performance status of 0. Adenocarcinoma was the most common histological subtype, accounting for 81.6%. Stage IIIB accounted for 57.1%. EGFR and ALK mutations were found in 24.5% of patients, and PD-L1 positivity was seen in 22.4%. The objective response rate was 46.9%, and the disease control rate was 91.8%. The median progression-free survival (PFS) was 26 months, and the median overall survival (OS) was not reached. Adverse events of any grade occurred in 61.2% of patients; treatment discontinuation due to adverse events occurred in 6.1%; and the most common grade 3-4 adverse event was pneumonitis, seen in 6.1% of patients. Durvalumab consolidation therapy after CCRT in stage III NSCLC patients is an effective treatment approach, with manageable adverse events.